Bioblast Pharma

Hope should not be rare

Fredric Price

Fredric Price

Executive Chairman of the Board of Directors

Fredric Price has been Executive Chairman of our Board of Directors since April 2014, having served as Chairman of the Board of Directors from April 2012 until April 2014. Since 2013, Mr. Price has served as a member of the Advisory Board of FDNA. From 2013 until 2014, he was Executive Chairman of the Board of Directors and from 2008 to 2013 Chairman of the Board of Directors and CEO of Chiasma. From 2004 to 2008, Mr. Price was Chairman of the Board of Directors of Omrix Biopharmaceuticals; from 2006 to 2012 a member of the Board of Directors of Enobia Pharma; from 2007 to 2010 a member of the Board of Directors of Pharmasset; from 2007 to 2011 Executive Chairman of the Board of Directors of Peptimmune; from 2004 to 2005 Executive Chairman of the Board of Directors of Zymenex; from 2000 to 2004 Chairman of the Board of Directors and CEO of BioMarin Pharmaceutical; and from 1994 to 2000 CEO and a member of the Board of Directors of Applied Microbiology.

As chairman and/or CEO, Mr. Price has raised more than $700 million in a variety of securities transactions, led a total of 21 M&A and licensing transactions, built FDA-approved facilities, and had drugs approved in the US as well as in international markets. His earlier experience includes having been Vice President of Finance and Administration and CFO of Regeneron Pharmaceuticals, the founder of the strategy consulting firm RxFDP, and Vice President of Pfizer Pharmaceuticals with both line and staff responsibilities. Mr. Price is a co-inventor of 13 issued US patents.

Mr. Price received a BA from Dartmouth College and an MBA from the Wharton School of the University of Pennsylvania.

Learn about other members of the Bioblast leadership team